Quarterly report pursuant to Section 13 or 15(d)

Revenue - Additional Information (Details)

v3.22.1
Revenue - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]    
Deferred revenue $ 2,197 $ 2,695
Contract with customer, liability, non-cancellable backlog $ 1,524  
Lease term 12 months  
Accounts receivable, net of allowances $ 3,346 4,662
Revenue recognized 694  
Deferred royalties 0 280
Accounts Receivable, Net And Other Assets    
Disaggregation of Revenue [Line Items]    
Accounts receivable, net of allowances 3,486 $ 4,824
Royalty    
Disaggregation of Revenue [Line Items]    
Revenue recognized 280  
Proceeds from upfront payment 300  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01    
Disaggregation of Revenue [Line Items]    
Remaining performance obligation, amount $ 902  
Remaining performance obligation, period 9 months  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01    
Disaggregation of Revenue [Line Items]    
Remaining performance obligation, amount $ 681  
Remaining performance obligation, period 1 year  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01    
Disaggregation of Revenue [Line Items]    
Remaining performance obligation, amount $ 614  
Remaining performance obligation, period  
Minimum    
Disaggregation of Revenue [Line Items]    
Accounts receivable payment terms 30 days  
Minimum | EksoHealth    
Disaggregation of Revenue [Line Items]    
Accounts receivable payment terms 12 months  
Maximum    
Disaggregation of Revenue [Line Items]    
Accounts receivable payment terms 90 days  
Maximum | EksoHealth    
Disaggregation of Revenue [Line Items]    
Accounts receivable payment terms 48 months